Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change

References

• Paul BZ, Kim S, Dangelmaier C, Nagaswami C, Jin J, Hartwig JH, Weisel JW, Daniel JL, Kunapuli SP. Dynamic regulation of microtubule coils in ADP-induced platelet shape change by p160ROCK (Rho-kinase). Platelets 2003; 14: 159–169
   PubMed Web of Science ®Google Scholar
• Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001; 62: 1153–1161
   PubMed Web of Science ®Google Scholar
• Cosentino F, Rubattu S, Savoia C, Venturelli V, Pagannonne E, Volpe M. Endothelial dysfunction and stroke. J Cardiovasc Pharmacol 2001; 38(Suppl 2)S75–78
   PubMed Web of Science ®Google Scholar
• Schafer A, Eigenthaler M, Bauersachs J. Platelet activation in heart failure. Clin Lab 2004; 50: 559–566
   PubMedGoogle Scholar
• Olas B, Wachowicz B. Role of reactive nitrogen species in blood platelet function. Platelets 2007; 23: 1–11
   Google Scholar
• Pepine CJ. The impact of nitric oxide in cardiovascular medicine: untapped potential utility. Am J Med 2009; 122: S10–15
   PubMed Web of Science ®Google Scholar
• Dangel O, Mergia E, Karlisch K, Groneberg D, Koesling D, Friebe A. NO-sensitive guanylyl cyclase is the only NO receptor mediating platelet inhibition. J Thromb Haemost 2010; 8: 1343–1352
   PubMed Web of Science ®Google Scholar
• Sheth S, Colman R. Platelet cAMP and cGMP phosphodiesterases. Platelets 1995; 6: 61–70
   PubMed Web of Science ®Google Scholar
• Ito M, Nishikawa M, Fujioka M, Miyahara M, Isaka N, Shiku H, Nakano T. Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021. Cell Signal 1996; 8: 575–581
   PubMed Web of Science ®Google Scholar
• Jensen BO, Selheim F, Doskeland SO, Gear AR, Holmsen H. Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide. Blood 2004; 104: 2775–2782
   PubMed Web of Science ®Google Scholar
• Bearer EL, Prakash JM, Manchester RD, Allen PG. VASP protects actin filaments from gelsolin: An in vitro study with implications for platelet actin reorganizations. Cell Motil Cytoskeleton 2000; 47: 351–364
   PubMed Web of Science ®Google Scholar
• Group ES, Halkes P, van Gijn J, Kappelle L, Koudstaal P, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet 2006; 20: 1665–1673
   Google Scholar
• Jensen BO, Skeidsvoll J, Holmsen H. A polarographic method for measuring dissolved nitric oxide. J Biochem Biophys Methods 1997; 35: 185–195
   PubMedGoogle Scholar
• Jensen BO, Holmsen H. Nitric oxide (NO)-platelet interactions: Inhibition is independent of the prostanoid and ADP pathways. Platelets 1995; 6: 83–90
   PubMed Web of Science ®Google Scholar
• Doskeland SO, Haga HJ. Measurement of adenosine 3′:5′-cyclic monophosphate by competitive binding to salt-dissociated protein kinase. Biochem J 1978; 174: 363–372
   PubMed Web of Science ®Google Scholar
• Doskeland SO, Ogreid D. Ammonium sulfate precipitation assay for the study of cyclic nucleotide binding to proteins. Methods Enzymol 1988; 159: 147–150
   PubMed Web of Science ®Google Scholar
• Eigenthaler M, Nolte C, Halbrugge M, Walter U. Concentration and regulation of cyclic nucleotides, cyclic- nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP- regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem 1992; 205: 471–481
   PubMedGoogle Scholar
• Mo E, Amin H, Bianco IH, Garthwaite J. Kinetics of a cellular nitric oxide/cGMP/phosphodiesterase-5 pathway. JBiolChem 2004; 279: 26149–26158
   PubMed Web of Science ®Google Scholar
• Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 2003; 22: 469–478
   PubMed Web of Science ®Google Scholar
• Aktas B, Utz A, Hoenig-Liedl P, Walter U, Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signalling in human platelets: In vitro/ex vivo studies. Stroke 2003; 34: 764–769
   PubMed Web of Science ®Google Scholar
• Thomas M, Francis S, Corbin J. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem 1990; 265: 14964–14970
   PubMed Web of Science ®Google Scholar
• Kotera J, Grimes KA, Corbin JD, Francis SH. cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5. Biochem J 2003; 372: 419–426
   PubMed Web of Science ®Google Scholar
• Antl M, von Bruhl ML, Eiglsperger C, Werner M, Konrad I, Kocher T, Wilm M, Hofmann F, Massberg S, Schlossmann J. IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation. Blood 2007; 109: 552–559
   PubMed Web of Science ®Google Scholar
• Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet JC. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 1986; 35: 1743–1751
   PubMed Web of Science ®Google Scholar
• Dunkern TR, Hatzelmann A. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell Signal 2005; 17: 331–339
   PubMed Web of Science ®Google Scholar
• Bult H, Fret HR, Jordaens FH, Herman AG. Dipyridamole Potentiates Platelet Inhibition by Nitric Oxide. Thrombosis Haemostasis 1991; 66: 343–349
   PubMed Web of Science ®Google Scholar
• Wilson LS, Elbatarny HS, Crawley SW, Bennett BM, Maurice DH. Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions. Proc Natl Acad Sci U S A 2008; 105: 13650–13655
   PubMed Web of Science ®Google Scholar
• Sabetkar M, Low SY, Bradley NJ, Jacobs M, Naseem KM, Richard Bruckdorfer K. The nitration of platelet vasodilator stimulated phosphoprotein following exposure to low concentrations of hydrogen peroxide. Platelets 2008; 19: 282–292
   PubMed Web of Science ®Google Scholar
• Sabetkar M, Naseem KM, Tullett JM, Friebe A, Koesling D, Bruckdorfer KR. Synergism between nitric oxide and hydrogen peroxide in the inhibition of platelet function: The roles of soluble guanylyl cyclase and vasodilator-stimulated phosphoprotein. Nitric Oxide 2001; 5: 233–242
   PubMed Web of Science ®Google Scholar
• Massberg S, Gruner S, Konrad I, Garcia Arguinzonis MI, Eigenthaler M, Hemler K, Kersting J, Schulz C, Muller I, Besta F, et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood 2004; 103: 136–142
   PubMed Web of Science ®Google Scholar
• Aszodi A, Pfeifer A, Ahmad M, Glauner M, Zhou XH, Ny L, Andersson KE, Kehrel B, Offermanns S, Fassler R. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J 1999; 18: 37–48
   PubMed Web of Science ®Google Scholar
• Harbeck B, Huttelmaier S, Schluter K, Jockusch BM, Illenberger S. Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin. J Biol Chem 2000; 275: 30817–30825
   PubMed Web of Science ®Google Scholar
• Lambrechts A, Kwiatkowski AV, Lanier LM, Bear JE, Vandekerckhove J, Ampe C, Gertler FB. cAMP-dependent protein kinase phosphorylation of EVL, a Mena/VASP relative, regulates its interaction with actin and SH3 domains. J Biol Chem 2000; 275: 36143–36151
   PubMed Web of Science ®Google Scholar
• Cutler LS, Christian CP, Feinstein MB. Cytochemical localization of adenylate cyclase in the dense tubule system of human blood platelets stimulated by forskolin, prostacyclin and prostaglandin D2. Biochim Biophys Acta 1985; 845: 403–410
   PubMed Web of Science ®Google Scholar
• White JG. Platelet structure. Platelets, AD Michelson. Academic Press, London 2006; 45–73
   Google Scholar
• Roberts W, Michno A, Aburima A, Naseem KM. Nitric oxide inhibits von Willebrand factor-mediated platelet adhesion and spreading through regulation of integrin alpha(IIb)beta(3) and myosin light chain. J Thromb Haemost 2009; 7: 2106–2115
   PubMed Web of Science ®Google Scholar
• Maxwell MJ, Westein E, Nesbitt WS, Giuliano S, Dopheide SM, Jackson SP. Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation. Blood 2007; 109: 566–576
   PubMed Web of Science ®Google Scholar
• Pigazzi A, Heydrick S, Folli F, Benoit S, Michelson A, Loscalzo J. Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets. J Biol Chem 1999; 274: 14368–14375
   PubMed Web of Science ®Google Scholar
• Plagemann PG. Transport and metabolism of adenosine in human erythrocytes: Effect of transport inhibitors and regulation by phosphate. J Cell Physiol 1986; 128: 491–500
   PubMed Web of Science ®Google Scholar
• Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: The Tromso Study, Tromso, Norway. J Thromb Haemost 2010; 8: 157–162
   PubMed Web of Science ®Google Scholar
• Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, Carberry J, Fouras A, Jackson SP. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009; 15: 665–673
   PubMed Web of Science ®Google Scholar